Compare AJANTA PHARMA with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TORRENT PHARMA AJANTA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 23.5 59.8 39.3% View Chart
P/BV x 4.1 6.3 65.5% View Chart
Dividend Yield % 0.9 0.8 104.9%  

Financials

 AJANTA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
TORRENT PHARMA
Mar-18
AJANTA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4221,550 91.7%   
Low Rs8981,144 78.5%   
Sales per share (Unadj.) Rs233.5354.7 65.8%  
Earnings per share (Unadj.) Rs44.040.1 109.7%  
Cash flow per share (Unadj.) Rs52.264.2 81.2%  
Dividends per share (Unadj.) Rs9.0014.00 64.3%  
Dividend yield (eoy) %0.81.0 74.7%  
Book value per share (Unadj.) Rs255.1273.1 93.4%  
Shares outstanding (eoy) m88.02169.22 52.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.03.8 130.8%   
Avg P/E ratio x26.433.6 78.5%  
P/CF ratio (eoy) x22.221.0 106.0%  
Price / Book Value ratio x4.54.9 92.2%  
Dividend payout %20.534.9 58.6%   
Avg Mkt Cap Rs m102,081227,897 44.8%   
No. of employees `0006.814.7 46.3%   
Total wages/salary Rs m4,30711,353 37.9%   
Avg. sales/employee Rs Th3,022.64,083.0 74.0%   
Avg. wages/employee Rs Th633.4772.3 82.0%   
Avg. net profit/employee Rs Th569.1461.3 123.4%   
INCOME DATA
Net Sales Rs m20,55460,021 34.2%  
Other income Rs m2112,988 7.1%   
Total revenues Rs m20,76563,009 33.0%   
Gross profit Rs m5,66413,493 42.0%  
Depreciation Rs m7214,086 17.6%   
Interest Rs m123,085 0.4%   
Profit before tax Rs m5,1439,310 55.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,529 50.3%   
Profit after tax Rs m3,8706,781 57.1%  
Gross profit margin %27.622.5 122.6%  
Effective tax rate %24.827.2 91.1%   
Net profit margin %18.811.3 166.6%  
BALANCE SHEET DATA
Current assets Rs m11,81252,623 22.4%   
Current liabilities Rs m3,77652,022 7.3%   
Net working cap to sales %39.11.0 3,901.3%  
Current ratio x3.11.0 309.2%  
Inventory Days Days77120 64.7%  
Debtors Days Days8276 107.0%  
Net fixed assets Rs m14,39885,016 16.9%   
Share capital Rs m175846 20.7%   
"Free" reserves Rs m22,27745,376 49.1%   
Net worth Rs m22,45246,222 48.6%   
Long term debt Rs m741,115 0.0%   
Total assets Rs m26,962142,432 18.9%  
Interest coverage x444.34.0 11,058.5%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.80.4 180.9%   
Return on assets %14.46.9 207.8%  
Return on equity %17.214.7 117.5%  
Return on capital %23.014.2 161.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68214,580 73.3%   
Fx outflow Rs m2,1023,600 58.4%   
Net fx Rs m8,58010,980 78.1%   
CASH FLOW
From Operations Rs m3,7488,942 41.9%  
From Investments Rs m-2,228-47,070 4.7%  
From Financial Activity Rs m-1,47534,174 -4.3%  
Net Cashflow Rs m45-3,655 -1.2%  

Share Holding

Indian Promoters % 73.8 71.5 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.0 22.1%  
FIIs % 7.6 12.6 60.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.8 193.2%  
Shareholders   20,968 26,511 79.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PLETHICO PHARMA  BIOCON   UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS